The Current Mature Market for Hormonal Contraceptives and Infertility Drugs is Estimated at US$7.1 Billion but is Forecast to Increase 40% to US$9.9 Billion by 2012.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c30827) has announced the addition of Spectra Intelligence Report "The Global Market for Hormonal Contraceptives and Infertility Drugs Infertility Drugs Definition Infertility drugs are medicines that help bring about pregnancy. Purpose Infertility is the inability of a man and woman to achieve pregnancy after at least a year of having regular sexual intercourse , 2005-2012" to their offering. Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. Novel contraceptive formulations with low side-effect profiles are providing women with flexible birthcontrol and menstrual menstrual /men·stru·al/ (men´stroo-al) pertaining to the menses or to menstruation. men·stru·al or men·stru·ous adj. Of or relating to menstruation. management options whilst also offering secondary indications to treat coexisting co·ex·ist intr.v. co·ex·ist·ed, co·ex·ist·ing, co·ex·ists 1. To exist together, at the same time, or in the same place. 2. endocrinological and gynaecological adj. 1. Of or pertaining to gynecology; same as gynecological. Adj. 1. gynaecological - of or relating to or practicing gynecology; "gynecological examination" gynecologic, gynecological disorders. Furthermore, the increasing global prevalence of infertility infertility, inability to conceive or carry a child to delivery. The term is usually limited to situations where the couple has had intercourse regularly for one year without using birth control. is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization fertilization, in biology, process in the reproduction of both plants and animals, involving the union of two unlike sex cells (gametes), the sperm and the ovum, followed by the joining of their nuclei. and embryo implantation implantation /im·plan·ta·tion/ (im?plan-ta´shun) 1. attachment of the blastocyst to the epithelial lining of the uterus, its penetration through the epithelium, and, in humans, its embedding in the stratum compactum of the , and reduce miscarriage miscarriage: see abortion. miscarriage or spontaneous abortion Spontaneous expulsion of an embryo or fetus from the uterus before it can live outside the mother. . Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate To insert a data signal into a carrier wave or direct current. See modulation. or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion but is forecast to increase 40% to US$9.9 billion by 2012. This report provides a detailed analysis of the global market for hormonal contraceptives and infertility drugs highlighting strategies for product extension and reformulation, sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. to 2012 for leading products, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into sector performance, which may enable the reader to make key assumptions about future markets and prospects. Report Highlights and Key Findings --The current market for the hormonal contraceptives and infertility drugs is valued at US$7.1 billion, which is forecast to increase 40% to US$9.9 billion by 2012 --Critical analysis of marketed hormonal contraceptives, reformulations, and infertility drugs --Analysis of over 10 key marketed products and inclusion of 38 R&D candidates identified in preclinical to clinical stages of development --Sales estimates (US$) to 2012 for leading products --Strategic insights for life-cycle optimization and product development --Commercial evaluation of leading reproductive health Within the framework of WHO's definition of health[1] as a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity, reproductive health, or sexual health/hygiene pharmacotherapies --Trend analysis of industry events and activities over past 2 years --Detailed R&D themes and clusters by therapy area --Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$) --High revenue-yielding prospects identified with projected sales estimations --R&D pipeline positioning for novel candidates --Market insights for product development and drug promotion What Can I Learn From This Report? --Which contraceptives and infertility drugs are the current and potential future market leaders? --Insights into the extent of reformulations for hormonal contraceptive products --What impact new drug approvals will have on the reproductive medicine drug market? --Which premarket drugs are identified as high-value products? --Which companies are developing hormonal contraceptives and infertility drugs? --Sales predictions to 2012 for leading contraceptives and infertility drugs --How will newcomers affect the product positioning of market leaders --What are niche market A niche market also known as a target market is a focused, targetable portion (subset) of a market sector. By definition, then, a business that focuses on a niche market is addressing a need for a product or service that is not being addressed by mainstream providers. opportunities in reproductive medicine? --What the future outlook holds for hormonal contraceptives and infertility pharmacotherapy pharmacotherapy /phar·ma·co·ther·a·py/ (-ther´ah-pe) treatment of disease with medicines. phar·ma·co·ther·a·py n. Treatment of disease through the use of drugs. ? --How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders --Which molecules and compounds are main R&D clusters in reproductive medicine? --Which of the pipeline candidates are identified as top prospects over the next decade and to 2020? Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered... Companies Mentioned: --Acrux --Agile Therapeutics --Akzo Nobel --Antares Pharma --Ardana --Astrazeneca --Barr Laboratories --Berlex --Enhance Biotech --Ferring --Gropep --Johnson & Johnson --Laboratoire Theramex --Ligand --Organon --Ortho-Mcneil Pharmaceuticals --Pfizer --Polydex Pharma --Sanofi-Aventis --Schering Ag --Serono --Solvay --Vitro Diagnostics --Wyeth For more information visit http://www.researchandmarkets.com/reports/c30827 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion